BL1107 Low dose
Phase 2Small molecule
BL1107 Low dose is one of 20 small molecule programs targeting Ocular Hypertension. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
187 competitors in Ocular Hypertension
#DrugCompanyPhaseTrials
1Alphagan
NovartisPhase 3
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Azopt
NovartisPhase 3
Ocupress
AbbViePhase 3
LUMIGAN
AbbViePhase 3
Krytantek
AbbViePhase 3
Bimatoprost/timolol
AbbViePhase 3
Preservative-Free Tafluprost
Merck & Co.Phase 3
Reference - LUMIGAN
AAmneal Pharmaceuticals, LLC
Phase 3
Duotrav
AAlcon Research
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BL1107 Low dose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBausch & Lomb Incorporated